Sumitomo Mitsui Trust Group
PRME icon

Sumitomo Mitsui Trust Group’s Prime Medicine PRME Stock Holding History

Sumitomo Mitsui Trust Group’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.9M Sell
2,412,984
-527,809
-18% -$1.75M 0.01% 677
2026
Q1 		$10.2M Sell
2,940,793
-304,713
-9% -$1.16M 0.01% 669
2025
Q4 		$11.3M Sell
3,245,506
-384,418
-11% -$1.71M 0.01% 672
2025
Q3 		$20.1M Buy
3,629,924
+2,035,406
+128% +$8.27M 0.01% 643
2025
Q2 		$3.94M Sell
1,594,518
-1,331,505
-46% -$2.05M ﹤0.01% 736
2025
Q1 		$5.82M Sell
2,926,023
-164,157
-5% -$419K ﹤0.01% 723
2024
Q4 		$9.02M Sell
3,090,180
-100,275
-3% -$352K 0.01% 713
2024
Q3 		$12.3M Sell
3,190,455
-47,930
-1% -$222K 0.01% 693
2024
Q2 		$16.6M Sell
3,238,385
-126,278
-4% -$766K 0.01% 663
2024
Q1 		$23.6M Sell
3,364,663
-154,366
-4% -$1.17M 0.02% 682
2023
Q4 		$31.2M Sell
3,519,029
-115,819
-3% -$892K 0.02% 611
2023
Q3 		$34.7M Buy
3,634,848
+571,097
+19% +$7.42M 0.03% 564
2023
Q2 		$44.9M Buy
3,063,751
+2,066,179
+207% +$28.8M 0.04% 503
2023
Q1 		$12.3M Buy
997,572
+509,346
+104% +$8.3M 0.01% 773
2022
Q4 		$9.07M Buy
+488,226
New +$8.82M 0.01% 793

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Sumitomo Mitsui Trust Group's PRME Position: Q2 2026 in Review

Sumitomo Mitsui Trust Group reduced its Prime Medicine (PRME) stake by 18% in Q2 2026, selling an estimated $1.75M and leaving 2,412,984 shares worth $8.9M. The position accounts for 0.01% of the portfolio, ranked #677.

Sumitomo Mitsui Trust Group first reported a position in PRME in Q4 2022 and has held it in 15 quarters since. The position peaked at $44.9M in Q2 2023. 187 funds tracked by Wall St. Rank hold PRME as of Q2 2026.

  • Sumitomo Mitsui Trust Group held 2,412,984 shares of Prime Medicine worth $8.9M as of Q2 2026.
  • Sumitomo Mitsui Trust Group sold 527,809 Prime Medicine shares in Q2 2026, an estimated $1.75M.
  • Prime Medicine made up 0.01% of Sumitomo Mitsui Trust Group's portfolio in Q2 2026, its #677 holding.
  • Sumitomo Mitsui Trust Group first reported a position in Prime Medicine in Q4 2022 and has held it in 15 quarters since.
  • Sumitomo Mitsui Trust Group's Prime Medicine position peaked at $44.9M in Q2 2023.
  • 187 funds tracked by Wall St. Rank held Prime Medicine as of Q2 2026.

Based on Sumitomo Mitsui Trust Group's 13F filing for Q2 2026, filed 30 Jul 2026.